2024 Annual Meeting | H69 - Moving Your Lab: When, Why, and How (Research Hub)

Date Sunday 04/14/24

Time 02:30 PM - 03:00 PM MDT Add To Calendar

Location Colorado Convention Center | Exhibit Hall D Lobby

Session Format This program will be presented in-person only

On Demand This program is not expected to be available in the meeting's On Demand product.

Event Type Hubs (Research)

Director(s) Peter B. Kang, MD, FAAN

Topic(s) General Neurology, Education, Research, and Methodology

Learning Objectives Are you moving your laboratory in the future? Bring your questions and join the discussion on career timing, family timing, transferring grants, IRB and human subject issues, IACUC and animal issues, transferring big data, unexpected expenses that may eat into your start-up package, what equipment you can take with you, parting on good terms with your old institution, and what to expect at your new institution for the first year after a move.

CME Available No CME available

Core Competencies Professionalism

Program Level Intermediate

Recommended Audience Fellow, Resident, General Neurologist, Specialist Neurologist

Teaching Styles Audience Participation

Program Materials Program Evaluations

Event Timeline
02:30 PM - 03:00 PM MDT	Speaker	Moving Your Lab: When, Why, and How Peter B. Kang, MD, FAAN

Faculty Disclosures
Peter B. Kang, MD, FAAN	Dr. Kang has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Novartis. Dr. Kang has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Sarepta Therapeutics. Dr. Kang has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Neurogene. Dr. Kang has received personal compensation in the range of $500-$4,999 for serving as a Consultant for NS Pharma. Dr. Kang has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Teneofour. Dr. Kang has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Lupin. Dr. Kang has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Wiley. The institution of Dr. Kang has received research support from Xtraordinary Joy Foundation. The institution of an immediate family member of Dr. Kang has received research support from Sarepta Therapeutics. The institution of Dr. Kang has received research support from Centers for Disease Control and Prevention (CDC). The institution of Dr. Kang has received research support from National Institutes of Health (NIH). The institution of Dr. Kang has received research support from Food and Drug Administration. The institution of Dr. Kang has received research support from National Initiative for Cockayne Syndrome. The institution of Dr. Kang has received research support from Greg Marzolf Jr Foundation. An immediate family member of Dr. Kang has received intellectual property interests from a discovery or technology relating to health care. Dr. Kang has received publishing royalties from a publication relating to health care. Dr. Kang has received personal compensation in the range of $5,000-$9,999 for serving as a Medical Advisory Board with National Initiative for Cockayne Syndrome. Dr. Kang has a non-compensated relationship as a Medical Advisory Board with Speak Foundation that is relevant to AAN interests or activities. Dr. Kang has a non-compensated relationship as a TRIAD Council with Hereditary Neuropathy Foundation that is relevant to AAN interests or activities. Dr. Kang has a non-compensated relationship as a President with Child Neurology Society that is relevant to AAN interests or activities. Dr. Kang has a non-compensated relationship as a Board Member with Child Neurology Foundation that is relevant to AAN interests or activities.